- Home
- MIDD vs ERAS Comparison
MIDD vs ERAS Comparison
Compare MIDD & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIDD | ERAS |
|---|---|---|
| Founded | 1888 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.3B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIDD | ERAS |
|---|---|---|
| Price | $113.15 | $14.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $155.67 | $24.11 |
| AVG Volume (30 Days) | 454.5K | ★ 4.8M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $3,201,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.92 | N/A |
| P/E Ratio | $1,127.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $102.15 | $2.11 |
| 52 Week High | $180.13 | $24.28 |
Technical Indicators
Market Signals| Indicator | MIDD | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 46.14 |
| Support Level | $110.98 | $13.56 |
| Resistance Level | $113.85 | $15.03 |
| Average True Range (ATR) | 2.30 | 1.03 |
| MACD | 1.21 | 0.04 |
| Stochastic Oscillator | 96.44 | 42.10 |
Price Performance
Historical ComparisonAbout MIDD Middleby Corporation (The)
The Middleby Corp is engaged in the foodservice industry. The company develops and manufactures a broad line of solutions used in commercial foodservice and food processing. The group showcases its solutions in the Middleby Innovation Kitchens for commercial foodservice and industrial baking and protein Innovation Centers for food processing solutions.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.